Meet Our Featured Speakers

The rapid advancement of mRNA therapeutics marks a defining moment in modern medicine. The global objective is clear: to translate breakthroughs in RNA science into scalable, safe, and accessible therapies for all. The potential of mRNA extends well beyond vaccines, shaping a new frontier in immuno-oncology, rare diseases, and protein-replacement therapies. Realising this promise, however, depends on the development of advanced delivery systems that ensure precise tissue targeting, repeat-dose safety, and strong stability across diverse global environments.

The most transformative advances in this sector lie in the engineering of lipid nanoparticles, polymer–lipid hybrids, GalNAc conjugation, and exosome-inspired vesicles that enable tissue specificity and sustained therapeutic efficacy. Developments such as cyclic-disulfide linkages and sterol-tuned lipid compositions significantly enhance endosomal escape, allowing for up to a three- to fourfold increase in mRNA release efficiency. Meanwhile, ligand-guided LNPs support selective delivery to extrahepatic tissues, mitigating the issue of liver accumulation that has long constrained systemic applications. These advancements unlock opportunities across oncology, infectious disease prevention, and metabolic and neurological disorders, with commercial potential estimated to exceed USD$580 billion over the coming decade. By integrating thermostable formulations, the industry also addresses global distribution and storage challenges, paving the way for broader access in low-resource regions.

At the same time, sustained investment in formulation science, AI-optimised systems, inhalable mRNA platforms, scalable manufacturing, and regulatory alignment remains essential. The creation of reproducible, stable, and biocompatible delivery vehicles will define the next era of mRNA therapeutics. Pharmaceutical leaders continue to work alongside material scientists, process engineers, and public health authorities to establish frameworks for rapid, compliant, and equitable deployment of mRNA-based treatments. The European mRNA Conference 2026 offers a platform for these collaborations, encouraging discussion on standards, investment strategies, and translational pathways that will shape the future of RNA medicine. This alignment of science, technology, and policy strengthens therapeutic precision and supports long-term sustainability for the mRNA industry worldwide.

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.